Protalix Biotherapeutics raised €36M in a funding round in Dec 2020. The company is based in Carmiel, Israel. Data as of 7 Aug 2026.
Confidence is the weaker of amount-FX and source evidence (the cascade rule). See methodology.
No investors disclosed for this round.
This is the company's only recorded round.
